Aurinia Pharmaceuticals
AUPH
191 hedge funds and large institutions have $895M invested in Aurinia Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 26 closing their positions.
104% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 26
63% more call options, than puts
Call options by funds: $202M | Put options by funds: $124M
14% more funds holding
Funds holding: 167 → 191 (+24)
9% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 55
3.94% less ownership
Funds ownership: 34.16% → 30.22% (-3.9%)
7% less capital invested
Capital invested by funds: $967M → $895M (-$71.7M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.8M |
| 2 |
MAM
Melqart Asset Management
London,
United Kingdom
|
+$21.7M |
| 3 |
Citigroup
New York
|
+$18M |
| 4 |
N
Natixis
Paris,
France
|
+$11.8M |
| 5 |
Renaissance Technologies
New York
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$85.5M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$49.8M |
| 3 |
Morgan Stanley
New York
|
-$46.2M |
| 4 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$17.7M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$11.5M |
AUPH Hedge Fund Activity: Q4 2021 in Review
191 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2021, worth a combined $895M — down 7.4% from $967M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new AUPH positions and 26 closed out — a net gain of 27 holders — while 60 added to existing stakes and 55 trimmed.
The largest buyer was BlackRock, adding an estimated $21.8M. The largest seller was Fidelity Investments, cutting an estimated $85.5M.
- 191 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2021, up from 167 in Q3 2021.
- Funds reported $895M of Aurinia Pharmaceuticals stock for Q4 2021, down 7.4% quarter-over-quarter.
- 53 funds opened new Aurinia Pharmaceuticals positions in Q4 2021 and 26 closed out, a net change of +27 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $21.8M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $85.5M sold.
Based on aggregated 13F filings for Q4 2021.